Analgesic effect via activation of blood flow

The phrase "Analgesic effect via activation of blood flow" is not the name of a specific molecule or molecular target. Analgesic effects associated with changes in blood flow can arise from the activation or inhibition of various molecular targets, such as the transient receptor potential channels (TRP channels, e.g., TRPM8 for menthol)[4], α2-adrenergic receptors (for drugs like dexmedetomidine)[1], or endogenous opioid receptors (modulated by beta-endorphin release following blood flow restriction training or exercise)[2][3][5]. These molecular systems can influence both pain perception and vascular tone but should be referenced by their specific protein or receptor name, not by a generalized physiological effect. This entry is not suitable as a canonical molecular target due to its lack of specificity, mixing of mechanisms and outcomes, and absence of a defined structure or nomenclature. The correct approach would be to identify the precise receptor, channel, or molecular mediator through which blood flow activation results in analgesic effects (such as "Transient receptor potential melastatin-8 channel" or "α2-adrenergic receptor").

Activation of ion channels (TRPM8, by menthol); Stimulation/inhibition of adrenergic receptors (α2-adrenergic, by dexmedetomidine); Endogenous opioid pathway modulation (beta-endorphin release during exercise)